Fig. 7

Proportion relapsed at each year: ≥4 versus 0 active T2 lesions at 12 months. a Placebo/delayed treatment group; b IFN β-1a 22 μg SC tiw group; c IFN β-1a 44 μg SC tiw group. p-values indicate differences between patients with differing lesion loads at 12 months within the treatment group. No statistically significant differences were seen in the IFN β-1a SC tiw groups. Values were calculated with a logistic regression model; number of relapses within previous 2 years, age, baseline EDSS score, and baseline burden of disease were independent variables, and p-values were calculated for the predictive effect of T2-lesion subgroups. *p < 0.05; **p < 0.01. EDSS: Expanded Disability Status Scale; IFN β-1a: interferon beta-1a; SC: subcutaneously; tiw: three times weekly